Metastatic hormone-receptor and HER-2 positive (triple-positive) breast cancer provides a treatment dilemma for clinicians.
The current guidelines offer a variety of options in the first and second line for metastatic breast cancer. A tailored treatment
approach is needed for the triple-positive metastatic breast cancer population.
Objective: To trend the therapeutic treatment selections for patients with metastatic, triple-positive breast cancer at a single,
Methods: The Abington Jefferson Health Tumor Registry and electronic medical records systems were used to retrospectively
identify patients with hormone and HER-2 positive metastatic disease who were treated at Abington Jefferson Health between
Results: It was found that there was variability across our population in the choice of what therapy was chosen for first, second
and fourth line of treatment. The majority of patients (12 out of 15) received combination therapy with trastuzumab. In the second
line, 7 out 8 patients received trastuzumab as part of their treatment regimen. In the third line, all 3 patients received trastuzumab
emtansine as part of their therapy regimen. For patients who were able to survive until the fourth line and beyond, several other
treatments were used.
Limitations: A small sample size is the major limitation in this study.
Conclusion: Although HR+/ Her2+ (triple positive) cancer cell type represents a subset of patients with metastatic breast
cancer, there is a general lack of consensus on how to best treat this patient population. More research needs to be conducted in
order for community Oncologic practitioners to be able to better coordinate care for patients with triple positive, metastatic breast